# Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00227682** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 2 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DIETARY_SUPPLEMENT:** ascorbic acid
- **DRUG:** arsenic trioxide
- **DRUG:** dexamethasone
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00227682
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Terminated early due to funding suspension by grant sponsor.
- **Last updated:** 2012-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227682, "Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00227682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*